Alzheimer’s Disease: Pathological Mechanisms and Recent Insights

Amyloidopathies cause neurodegeneration in a substantial portion of the elderly population. Improvements in long term health care have made elderly individuals a large and growing demographic group, marking these diseases as a major public health concern. Alzheimer’s Disease (AD) is the most studied form of neurodegenerative amyloidopathy. Although our understanding of AD is far from complete, several decades of research have advanced our knowledge to the point where it is conceivable that some form of disease modifying therapy may be available in the near future. These advances have been built on a strong mechanistic understanding of the disease from its underlying genetics, molecular biology and clinical pathology. Insights derived from the study of other neurodegenerative diseases, such as some forms of frontotemporal dementia, have been critical to this process. This knowledge has allowed researchers to construct animal models of the disease process that have paved the way towards the development of therapeutics. However, what was once thought to be a straightforward problem has evolved into a series of disappointing outcomes. Examination of pathways common to all neurodegenerative diseases, including the cellular mechanisms that clear misfolded proteins and their regulation, may be the best way to move forward.

[1]  Lewis E Kazis,et al.  Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.

[2]  B. de Strooper,et al.  Loss‐of‐function presenilin mutations in Alzheimer disease , 2007, EMBO reports.

[3]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[4]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[5]  D. Holtzman,et al.  Active and passive immunotherapy for neurodegenerative disorders. , 2008, Annual review of neuroscience.

[6]  J. Hardy,et al.  Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice , 2005, Neuron.

[7]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[8]  Thomas C. Südhof,et al.  A Transcriptively Active Complex of APP with Fe65 and Histone Acetyltransferase Tip60 , 2001, Science.

[9]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[10]  J. McLaurin,et al.  Interaction of human and mouse Aβ peptides , 2004 .

[11]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[12]  J. Schröder,et al.  Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42 , 2005, Neurobiology of Aging.

[13]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[14]  W. Markesbery,et al.  Aβ solubility and deposition during AD progression and in APP×PS-1 knock-in mice , 2007, Neurobiology of Disease.

[15]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[16]  C. Mirkin,et al.  Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Shulman,et al.  Evidence for a common pathway linking neurodegenerative diseases , 2009, Nature Genetics.

[18]  Sudha Seshadri,et al.  Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. , 2009, JAMA.

[19]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[20]  J. Busciglio,et al.  Different Conformations of Amyloid β Induce Neurotoxicity by Distinct Mechanisms in Human Cortical Neurons , 2006, The Journal of Neuroscience.

[21]  M. Wolfe When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. , 2007, EMBO reports.

[22]  L. Hersh,et al.  Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Guido Kroemer,et al.  Autophagy in the Pathogenesis of Disease , 2008, Cell.

[24]  W. Markesbery,et al.  AD lesions and infarcts in demented and non‐demented Japanese‐American men , 2005, Annals of neurology.

[25]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[26]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[27]  S. Younkin,et al.  Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition , 2001, Neurobiology of Aging.

[28]  B. de Strooper,et al.  FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. , 2002, Neurobiology of aging.

[29]  Yama Akbari,et al.  Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. , 2005, Neurobiology of aging.

[30]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[31]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[32]  J. McLaurin,et al.  Interaction of human and mouse Abeta peptides. , 2004, Journal of neurochemistry.

[33]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[34]  George Perry,et al.  Leptin: a novel therapeutic strategy for Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[35]  J. Luchsinger,et al.  Adiposity, type 2 diabetes, and Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[36]  L. Lannfelt,et al.  Animal models of amyloid‐β‐related pathologies in Alzheimer’s disease , 2010, The FEBS journal.

[37]  H. Lester,et al.  Rodent Aβ Modulates the Solubility and Distribution of Amyloid Deposits in Transgenic Mice* , 2007, Journal of Biological Chemistry.

[38]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[39]  R. Kayed,et al.  Soluble Amyloid Oligomers Increase Bilayer Conductance by Altering Dielectric Structure , 2006, The Journal of general physiology.

[40]  Jason Eriksen,et al.  A decade of modeling Alzheimer's disease in transgenic mice. , 2006, Trends in genetics : TIG.

[41]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  F. Gage,et al.  Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice , 2003, The Journal of Neuroscience.

[43]  R. Berry,et al.  Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Lucas,et al.  Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options , 2009, European journal of neurology.

[45]  Kristina D. Micheva,et al.  Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques , 2009, Proceedings of the National Academy of Sciences.

[46]  Philippe Amouyel,et al.  The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. , 2010, Trends in genetics : TIG.

[47]  M. Kirkitadze,et al.  Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Kristine Yaffe,et al.  Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study , 2005, BMJ : British Medical Journal.

[49]  S. Love,et al.  Decreased Expression and Activity of Neprilysin in Alzheimer Disease Are Associated With Cerebral Amyloid Angiopathy , 2006, Journal of neuropathology and experimental neurology.

[50]  T. Saido,et al.  Metabolic regulation of brain Abeta by neprilysin. , 2001, Science.

[51]  S. Gauthier,et al.  Alzhemed: a potential treatment for Alzheimer's disease. , 2007, Current Alzheimer research.

[52]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[53]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[54]  K. Jellinger,et al.  Formation and development of Lewy pathology: a critical update , 2009, Journal of Neurology.

[55]  Christopher Clark,et al.  Disease-modifying therapies for Alzheimer disease , 2007, Neurology.

[56]  R. Green,et al.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. , 2008, Archives of neurology.

[57]  S. Gauthier,et al.  Effect of tramiprosate in patients with mild-to-moderate alzheimer’s disease: Exploratory analyses of the MRI sub-group of the alphase study , 2009, The journal of nutrition, health & aging.

[58]  D. Bennett,et al.  The neuropathology of older persons with and without dementia from community versus clinic cohorts. , 2009, Journal of Alzheimer's disease : JAD.

[59]  J. Lamb,et al.  Characterisation of the binding of amyloid imaging tracers to rodent Aβ fibrils and rodent-human Aβ co-polymers , 2006 .

[60]  R. Kayed,et al.  Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases* , 2004, Journal of Biological Chemistry.

[61]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[62]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[63]  Manuel Buttini,et al.  Mice as models: transgenic approaches and Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[64]  S. Pimplikar,et al.  The γ-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[66]  Charles D. Smith,et al.  Human cerebral neuropathology of Type 2 diabetes mellitus. , 2009, Biochimica et biophysica acta.

[67]  D. Westaway,et al.  Transgenic mouse models of Alzheimer's disease , 2001, Physiology & Behavior.

[68]  Arlan Richardson,et al.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. , 2010, The Journal of biological chemistry.

[69]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[70]  D. Rubinsztein,et al.  Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases , 2010, The Journal of Biological Chemistry.

[71]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[72]  J. Hardy,et al.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.

[73]  G. Higgins,et al.  Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein , 1991, Nature.

[74]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[75]  D L Sparks,et al.  Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol‐Lowering Treatment (ADCLT) trial , 2006, Acta neurologica Scandinavica. Supplementum.

[76]  Yu-Min Kuo,et al.  APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques† , 2002 .

[77]  M. Hill,et al.  A Two-Year Study with Fibrillar β-Amyloid (Aβ) Immunization in Aged Canines: Effects on Cognitive Function and Brain Aβ , 2008, The Journal of Neuroscience.

[78]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[79]  B. Strooper,et al.  FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction , 2002, Neurobiology of Aging.

[80]  E. Masliah,et al.  Increased Extracellular Amyloid Deposition and Neurodegeneration in Human Amyloid Precursor Protein Transgenic Mice Deficient in Receptor-Associated Protein , 2002, The Journal of Neuroscience.

[81]  Yama Akbari,et al.  Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders , 2005, Neurobiology of Aging.

[82]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[83]  S. Haneuse,et al.  Pathological correlates of dementia in a longitudinal, population‐based sample of aging , 2007, Annals of neurology.

[84]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[85]  D. Holtzman,et al.  Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.

[86]  J. Lamb,et al.  Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. , 2006, Biochemical and biophysical research communications.

[87]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[88]  M. Wolfe When loss is gain: reduced presenilin proteolytic function leads to increased Aβ42/Aβ40 , 2007 .

[89]  B. Yankner,et al.  Neural mechanisms of ageing and cognitive decline , 2010, Nature.

[90]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[91]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[92]  H. Münzberg,et al.  Leptin receptor action and mechanisms of leptin resistance , 2005, Cellular and Molecular Life Sciences.

[93]  W. Markesbery,et al.  Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. , 2007, Neurobiology of disease.

[94]  D. Woodruff-Pak,et al.  Animal models of Alzheimer's disease: therapeutic implications. , 2008, Journal of Alzheimer's disease : JAD.

[95]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[96]  S. Hendrix,et al.  Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.

[97]  H. Arai,et al.  Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease , 2005, Annals of neurology.

[98]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[99]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[100]  M. Staufenbiel,et al.  APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. , 2002, Biochemistry.

[101]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[102]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[103]  D. Selkoe,et al.  The Intracellular Domain of the β-Amyloid Precursor Protein Is Stabilized by Fe65 and Translocates to the Nucleus in a Notch-like Manner* , 2001, The Journal of Biological Chemistry.

[104]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[105]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[106]  Peter T Nelson,et al.  Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort: Neuritic Plaques and Neurofibrillary Tangles "Do Count" When Staging Disease Severity , 2007, Journal of neuropathology and experimental neurology.

[107]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[108]  K. Heilman,et al.  Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank , 2002, Alzheimer disease and associated disorders.

[109]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[110]  John Q. Trojanowski,et al.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update , 2009, Acta Neuropathologica.

[111]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[112]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[113]  W. K. Cullen,et al.  Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization , 2008, The Journal of Neuroscience.

[114]  R. Hébert,et al.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. , 2002, American journal of epidemiology.

[115]  M. Staufenbiel,et al.  Neprilysin-sensitive Synapse-associated Amyloid-β Peptide Oligomers Impair Neuronal Plasticity and Cognitive Function* , 2006, Journal of Biological Chemistry.

[116]  F. Hobbs,et al.  65+ in the United States. , 1996 .

[117]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.